SANDOZ ORPHENADRINE 100 MG
ORPHENADRINE CITRATE : 100 MG · DIN 02243559 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is SANDOZ ORPHENADRINE?
SANDOZ ORPHENADRINE 100 MG contains ORPHENADRINE CITRATE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02243559, held by SANDOZ CANADA INCORPORATED, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Dec-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02243559 |
|---|---|
| Brand name | SANDOZ ORPHENADRINE |
| Generic / active ingredient | ORPHENADRINE CITRATE : 100 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 100 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | M03BC01 ORPHENADRINE (CITRATE) |
| AHFS class | 52:28.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Dec-2005 |
| Original market date | 2006-03-22 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M03BC01 ORPHENADRINE (CITRATE). 1 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| NORFLEX | 100 MG | TABLET (EXTENDED-RELEASE) | VALEANT CANADA LP / VALEANT CANADA S.E.C. | CANCELLED POST MARKET | DIN 01966154 |
| NORFLEX | 30 MG | LIQUID | VALEANT CANADA LP / VALEANT CANADA S.E.C. | CANCELLED POST MARKET | DIN 01966162 |
| ORFENACE TABLET 100MG | 100 MG | TABLET | STERIMAX INC | DORMANT | DIN 02047535 |
| ORPHENADRINE CITRATE INJECTION, USP | 30 MG | LIQUID | STERIMAX INC | DORMANT | DIN 02229731 |
Who else supplies ORPHENADRINE (CITRATE) worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ORPHENADRINE (CITRATE) appears in 27 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.